Article Details
Retrieved on: 2024-12-07 17:18:44
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses BioAge Labs' halted study of azelaprag, a peptide therapeutic for obesity, due to liver enzyme concerns. This relates to biopharma within the context of developing weight loss drugs, involving companies like Eli Lilly and Novo Nordisk.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here